Elekta absorbs heavy restructuring charge as margin initiatives start to bite

Elekta AB ( ($SE:EKTA.B) ) just unveiled an update.

Elekta reported a mixed third quarter, with net sales up 2 percent in constant currencies but down 10 percent in SEK, as currency headwinds and tariffs weighed on reported results. The company maintained a strong book-to-bill ratio of 1.17, driven by robust order intake in China, the U.S., and Europe, and saw improved adjusted gross margin helped by new product launches and better pricing.

Profitability on an adjusted basis held up, with a slightly higher adjusted EBIT margin, but restructuring charges of SEK 417 million tied to a major operating model overhaul pushed net income sharply lower and reduced cash flow. Management said more than 80 percent of planned workforce reductions are completed, targeting over SEK 500 million in annual cost savings by fiscal 2026/27, as Elekta doubles down on focused R&D, U.S. competitiveness, deeper localization in China, and cost-of-goods initiatives to bolster margins and support future growth.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

More about Elekta AB

Elekta AB is a Sweden-based medical technology company specializing in radiation therapy, radiosurgery, and related oncology software and services. The company focuses on cancer care solutions for hospitals and clinics worldwide, with key markets in Europe, the U.S., and China, and emphasizes innovation in adaptive treatments and integrated hardware-software platforms.

Average Trading Volume: 1,101,557

Technical Sentiment Signal: Hold

Current Market Cap: SEK21.22B

For an in-depth examination of EKTA.B stock, go to TipRanks’ Overview page.